Pricing
  1. US-listed companies
  2. HALOZYME THERAPEUTICS, INC.
  3. Financials
  4. Research & development

HALOZYME THERAPEUTICS, INC. (HALO)

Market cap
$7.9B
P/E ratio
SummaryFinancials
Period EndResearch & development (Million USD)YoY (%)
Dec 31, 202479+3.52%
Dec 31, 202376+14.65%
Dec 31, 202267+86.72%
Dec 31, 202136+4.19%
Dec 31, 202034-75.69%
Dec 31, 2019141-6.29%
Dec 31, 2018150-0.26%
Dec 31, 2017151-0.13%
Dec 31, 2016151+61.79%
Dec 31, 201593+16.99%
Dec 31, 201480-17.53%
Dec 31, 201397+37.97%
Dec 31, 201270+21.68%
Dec 31, 201158

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat